Table 3.
Pharmaceutical and radiation therapy exposures of participants
| Variable and Category | Frequency | Percentage |
|---|---|---|
| Current ACEi | ||
| No | 2512 | 91.3 |
| Yes | 133 | 4.8 |
| Missing | 108 | 3.9 |
| Current ARB | ||
| No | 2626 | 95.4 |
| Yes | 26 | 0.9 |
| Missing | 101 | 3.7 |
| Ever calcineurin inhibitor | ||
| No | 2693 | 97.8 |
| Yes | 58 | 2.1 |
| Missing | 2 | 0.1 |
| Aminoglycoside | ||
| No | 1684 | 61.2 |
| Yes | 1069 | 38.8 |
| Fungal infection | ||
| No | 2499 | 90.8 |
| Yes | 254 | 9.2 |
| Total doses (original and liposomal amphotericin B), n=248a | ||
| Mean (SD) | 23.5 (26.1) | |
| Median (IQR) | 14.0 (7.0–31.0) | |
| Doses of AmBisome, n=14a | ||
| Mean (SD) | 34.0 (22.2) | |
| Median (IQR) | 33.5 (26.0–50.0) | |
| Doses of Abelcet, n=12a | ||
| Mean (SD) | 16.4 (16.7) | |
| Median (IQR) | 11.0 (4.5–25.0) | |
| Doses of Abelcet/AmBisome, n=23a | ||
| Mean (SD) | 29.3 (21.0) | |
| Median (IQR) | 31.0 (11.0–38.0) | |
| Doses of amphotericin B (n=233)b | ||
| Mean (SD) | 18.1 (16.9) | |
| Median (IQR) | 13.0 (6.0–24.0) | |
| Renal radiation | ||
| No | 2314 | 84.0 |
| Yes | 439 | 16.0 |
| Percentage of total renal mass for V5, n=367 percentage >0c | ||
| Mean (SD) | 67.5 (34.6) | |
| Median (IQR) | 78.3 (34.6–100.0) | |
| Percentage of total renal mass for V10, n=359 percentage >0 | ||
| Mean (SD) | 58.6 (38.0) | |
| Median (IQR) | 53.4 (22.3–100.0) | |
| Percentage of total renal mass for V15, n=249 percentage >0 | ||
| Mean (SD) | 30.7 (28.6) | |
| Median (IQR) | 22.2 (8.4–44.7) | |
| Percentage of total renal mass for V20, n=197 percentage >0 | ||
| Mean (SD) | 20.3 (21.6) | |
| Median (IQR) | 13.0 (4.8–26.7) | |
Missing data are indicated.
a
Six patients.
b
Seven patients.
c
Sixty-two patients.